Ronald Nathaniel Marcus MD
Neuropsychiatry, Psychopharmacology
SVP at Bristol-Myers Squibb
Join to View Full Profile
Karuna TherapeuticsBoston, MA 02110
Phone+1 203-376-3914
Dr. Marcus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Bristol-Myers Squibb, SVP Clinical Development in Psychiatry
Karuna Therapeutics SVP Clinical Development
Supernus - VP of R&D
Cerecor - Chief Medical Officer and Head of Regulatory Affairs
Spinifex Pharmaceuticals - Chief Medical Officer
Bristol Myers Squibb - 23 years, Executive Director Neuroscience Clinical Research
Education & Training
NewYork–Presbyterian/Westchester DivisionFellowship, 1987 - 1989
New York Presbyterian Hospital (Cornell Campus)/WestchesterResidency, Psychiatry, 1984 - 1987- Nassau University Medical CenterInternship, Internal Medicine, 1983 - 1984
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1983- University of VirginiaBA, Psychology, 1975 - 1979
Certifications & Licensure
MD State Medical License 2022 - 2025
CT State Medical License 1985 - 2022
NY State Medical License 1984 - 1992
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Tri...Inder Kaul, Amy Claxton, Sharon Sawchak, Colin Sauder, Stephen K Brannan
The Journal of Clinical Psychiatry. 2025-02-26 - 7 citationsA proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression.Adelaide S. Robb, Stefan Schwabe, Gianpiera Ceresoli-Borroni, Azmi Nasser, Chungping Yu
Postgraduate Medicine. 2019-02-14 - 9 citationsEfficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.J. Craig Nelson, Zia Rahman, Kimberly K. Laubmeier, James M. Eudicone, Robert D. McQuade
CNS Spectrums. 2014-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
